April 2021: First results of the randomized phase III PenelopeB trial


April 2021: First results of the randomized phase III PenelopeB trial

We are delighted to inform you that the first results of the randomized phase III PenelopeB trial have been published on a Rapid Communications basis in Journal of Clinical Oncology.

About one third of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy will relapse. Thus, additional therapy is needed. Palbociclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor demonstrating efficacy in the metastatic setting. The randomized phase III PenelopeB study evaluated the addition of the CDK4/6 inhibitor palbociclib to endocrine therapy as post-neoadjuvant treatment for HR-positive/HER2-negative, breast cancer patients with high risk of relapse (clinical pathological staging-estrogen receptor grading score ≥ 3 or 2 and ypN+) after neoadjuvant chemotherapy. Patients received either palbociclib 125 mg orally once daily for 21 days followed by 1 week off treatment for a total duration of 13 4-week cycles or matching placebo in addition to standard adjuvant endocrine therapy at the discretion of the investigator given for at least 5 years. The primary endpoint was invasive disease-free survival (iDFS). Secondary endpoints included iDFS excluding second primary invasive nonbreast cancers, distant disease-free survival, overall survival, locoregional relapse-free interval, safety, and compliance. After a median follow-up of 43 months the addition of 1 year palbociclib to standard adjuvant endocrine therapy did not significantly improve iDFS. The estimated 3-year iDFS was 81.2% (95%CI 77.8%-84.1%) with palbociclib and 77.7% (95%CI 74.1%-80.9%) with placebo. No new safety signals were observed. PenelopeB is the first study showing mature iDFS results on a CDK4/6 inhibitor as part of (post-neo)adjuvant therapy in early breast cancer. Further translational research and subgroup analyses are ongoing.

Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd